-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Johnson and Johnson announced new open label extension data for its Phase III clinical study VOYAGE 1, which showed that after nearly five years of treatment with TREMFYA (guselkumab), adult patients with moderate to severe plaque psoriasis consistently maintained high skin removal rates with no new safety signals.
week 252 of the
guselkumab joint treatment, 84% of patients received a Psoriasis Regional Severity Index (PASI) 90 response (a 90% increase in PASI scores compared to the baseline), and 82.4% of patients with an overall assessment (IGA) score of 0 (clear) or 1 (almost clear) (IGA 0/1).
no new security issues were observed after 264 weeks.
about TREMFYA (guselkumab) Guselkumab is the first approved monoclonal antibody of all-human-targeted interleukin (IL)-23, which selectively binds to the p19 sub-base of IL-23 and inhibits its interaction with the IL-23 receptor.
IL-23 is an important cause of inflammatory diseases such as psoriasis.
photo source: The most common form of psoriasis is plaque-like psoriasis, which usually causes areas of the skin that are thick, red or inflamed to be covered with psoriasis, called plaques.
about 14 million people in Europe suffer from psoriasis, often resulting in a huge physical and mental burden.
psoriasis is also associated with a variety of complications, including psoriasis arthritis, cardiovascular disease, metabolic syndrome, chronic obstructive pulmonary disease (COPD) and osteoporosis.
.